Research And Markets Research And Markets
0 CHECKOUT

Brain Metastasis - Pipeline Review, H2 2015

  • ID: 3384507
  • July 2015
  • 194 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • BBB Therapeutics B.V.
  • e-Therapeutics Plc
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • MORE

‘Brain metastasis - Pipeline Review, H2 2015’, provides an overview of the Brain metastasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain metastasis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • BBB Therapeutics B.V.
  • e-Therapeutics Plc
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Brain Metastasis Overview

Therapeutics Development

Pipeline Products for Brain Metastasis - Overview

Pipeline Products for Brain Metastasis - Comparative Analysis

Brain Metastasis - Therapeutics under Development by Companies

Brain Metastasis - Therapeutics under Investigation by Universities/Institutes

Brain Metastasis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Brain Metastasis - Products under Development by Companies

Brain Metastasis - Products under Investigation by Universities/Institutes

Brain Metastasis - Companies Involved in Therapeutics Development

AbbVie Inc.

AngioChem Inc.

BBB Therapeutics B.V.

biOasis Technologies Inc.

Bristol-Myers Squibb Company

Diffusion Pharmaceuticals LLC

e-Therapeutics Plc

Exelixis, Inc.

GlaxoSmithKline Plc

Hutchison MediPharma Limited

Komipharm International Co., Ltd.

Nektar Therapeutics

Nerviano Medical Sciences S.r.l.

Novartis AG

Oncothyreon Inc.

Pfizer Inc.

Philogen S.p.A.

Phosplatin Therapeutics LLC

Puma Biotechnology, Inc.

Radius Health, Inc.

Sanofi

Spectrum Pharmaceuticals, Inc.

Tocagen Inc.

Brain Metastasis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

2B3-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ANG-1005 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ANG-4043 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BT-2111 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cabazitaxel - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cabozantinib s-malate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ceritinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

dacomitinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

etirinotecan pegol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ETS-2101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HMPL-813 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ipilimumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

irbinitinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KML-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

lucanthone hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MDNA-55 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

neratinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

nimotuzumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NMSE-973 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PB-357 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PF-06463922 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

plinabulin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PT-112 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RAD-1901 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

radretumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RRX-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TPI-287 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

transcrocetinate sodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Metastatic Brain Tumor - Drug Profile

Product Description

Mechanism of Action

R&D Progress

veliparib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

vocimagene amiretrorepvec + flucytosine ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

X-82 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Brain Metastasis - Recent Pipeline Updates

Brain Metastasis - Dormant Projects

Brain Metastasis - Discontinued Products

Brain Metastasis - Product Development Milestones

Featured News & Press Releases

Aug 28, 2014: Radius Health Reports Proof of Mechanism for RAD1901 and Presentation at 4th Annual Brain Metastases Research and Emerging Therapy Conference in September

Nov 12, 2013: Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone

Oct 08, 2013: Angiochem to Present at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Jul 29, 2013: Nerviano Medical Sciences researchers report data on a novel molecule inhibitor of HSP90

Apr 09, 2013: biOasis Provides Update On BT2111-Herceptin Program

Dec 03, 2012: Geron Discontinues Development Of Brain Cancer Drug Candidate GRN1005

Dec 22, 2011: Geron Initiates Phase II Trial Of GRN1005 In Brain Metastases Arising From Lung Cancer

Nov 15, 2011: Geron Presents Final Phase I Clinical Data On GRN1005 At AACR-NCI-EORTC

Jun 07, 2010: Angiochem Presents Complete Phase I/II Clinical Data Of ANG1005 For Treatment Of Brain Metastases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Brain Metastasis, H2 2015

Number of Products under Development for Brain Metastasis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

Brain Metastasis - Pipeline by AbbVie Inc., H2 2015

Brain Metastasis - Pipeline by AngioChem Inc., H2 2015

Brain Metastasis - Pipeline by BBB Therapeutics B.V., H2 2015

Brain Metastasis - Pipeline by biOasis Technologies Inc., H2 2015

Brain Metastasis - Pipeline by Bristol-Myers Squibb Company, H2 2015

Brain Metastasis - Pipeline by Diffusion Pharmaceuticals LLC, H2 2015

Brain Metastasis - Pipeline by e-Therapeutics Plc, H2 2015

Brain Metastasis - Pipeline by Exelixis, Inc., H2 2015

Brain Metastasis - Pipeline by GlaxoSmithKline Plc, H2 2015

Brain Metastasis - Pipeline by Hutchison MediPharma Limited, H2 2015

Brain Metastasis - Pipeline by Komipharm International Co., Ltd., H2 2015

Brain Metastasis - Pipeline by Nektar Therapeutics, H2 2015

Brain Metastasis - Pipeline by Nerviano Medical Sciences S.r.l., H2 2015

Brain Metastasis - Pipeline by Novartis AG, H2 2015

Brain Metastasis - Pipeline by Oncothyreon Inc., H2 2015

Brain Metastasis - Pipeline by Pfizer Inc., H2 2015

Brain Metastasis - Pipeline by Philogen S.p.A., H2 2015

Brain Metastasis - Pipeline by Phosplatin Therapeutics LLC, H2 2015

Brain Metastasis - Pipeline by Puma Biotechnology, Inc., H2 2015

Brain Metastasis - Pipeline by Radius Health, Inc., H2 2015

Brain Metastasis - Pipeline by Sanofi, H2 2015

Brain Metastasis - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015

Brain Metastasis - Pipeline by Tocagen Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Brain Metastasis Therapeutics - Recent Pipeline Updates, H2 2015

Brain Metastasis - Dormant Projects, H2 2015

Brain Metastasis - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Brain Metastasis, H2 2015

Number of Products under Development for Brain Metastasis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

AbbVie Inc.
AngioChem Inc.
BBB Therapeutics B.V.
biOasis Technologies Inc.
Bristol-Myers Squibb Company
Diffusion Pharmaceuticals LLC
e-Therapeutics Plc
Exelixis, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
Komipharm International Co., Ltd.
Nektar Therapeutics
Nerviano Medical Sciences S.r.l.
Novartis AG
Oncothyreon Inc.
Pfizer Inc.
Philogen S.p.A.
Phosplatin Therapeutics LLC
Puma Biotechnology, Inc.
Radius Health, Inc.
Sanofi
Spectrum Pharmaceuticals, Inc.
Tocagen Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db